You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中關村(000931.SZ): 富馬酸比索洛爾片擬中標第二批藥品集採
格隆匯 01-20 09:02

格隆匯1月20日丨中關村(000931.SZ)公佈,2020年1月17日,公司全資子公司北京中關村四環醫藥開發有限責任公司之控股子公司華素製藥參加了國家組織藥品集中採購和使用聯合採購辦公室組織實施的第二批國家組織藥品集中採購的投標。公司已通過國家藥品監督管理局仿製藥質量和療效一致性評價的仿製藥品富馬酸比索洛爾片在該次投標中擬中標。

富馬酸比索洛爾片(2.5mg)及富馬酸比索洛爾片(5mg)擬中標價格分別為2.5mg×10片3.73元/盒,5mg×10片6.34元/盒;供應省(區)為北京、天津、河北、山西、遼寧、福建、江西、山東、廣西、海南、貴州、陝西、甘肅、青海、寧夏。

該次富馬酸比索洛爾片擬中選企業為2家,根據聯合採購辦公室發佈的《全國藥品集中採購文件》:全國實際中選企業為2家的,首年約定採購量為首年約定採購量計算基數的60%,本輪採購週期原則上為2年。採購週期中,醫療機構應優先使用該次藥品集中採購中選藥品,並確保完成約定採購量。採購週期內若提前完成當年約定採購量,超過部分中選企業仍按中選價進行供應,直至採購週期屆滿。

該次華素製藥為第二順位中標企業,中標價格較為合理,有利於進一步擴大該產品市場佔有率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account